# Targeting Inflammatory Pathways in Cancer: Novel Insights into Tumorigenesis and Personalized Therapeutic Approaches

G.R. Nivashini[1,*], Lalatendu Moharana[2], Ashish Jawarkar[3], Komal Parashar[4], Tarun Parashar[5] and Dinesh Kumar Yadav[6]

[1]*Department of Radiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SI MATS), Saveetha University, Chennai 602105; Tamil Nadu, India*

[2]*Department of Onco-Medicine, IMS and SUM Hospital, Siksha' O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India*

[3]*Department of Pathology, Parul Institute of Medical Sciences & Research, Parul University, Vadodara, Gujarat, India*

[4]*Centre of Research Impact and Outcome, Chitkara University, Rajpura- 140417, Punjab, India*

[5]*School of Pharmacy & Research, Dev Bhoomi Uttarakhand University, Dehradun, India*

[7]*Department of Pharmacognosy, College of Pharmacy, SGT University, Gurugram, Haryana, India*

**Abstract:** A characteristic feature of cancer is chronic inflammation, which leads to tumor formation, development, and metastasis. NF-KB, STAT3, COX-2, and IL-6/IL-1b inflammatory signaling pathways are important in regulating the tumor microenvironment through cell proliferation, survival, angiogenesis, and immune evasion. When constantly activated, these pathways result in genomic instability and epigenetic alterations, which provide a favorable condition of malignant transformation. These inflammatory pathways are regularly usurped by oncogenes to stimulate tumor growth and survival. Recent research has been aimed at attacking key inflammatory mediators, including cytokines, transcription factors, and upstream kinases. Anti-inflammatory drugs, such as selective JAK/STAT, IKK, and COX-2, have a great promise as therapeutic agents. As an example, the volume of tumors in pre-clinical models has been reduced by 40% with treatment using JAK/STAT inhibitors and morbidity by 30% with COX-2 inhibition in patients with high-risk colorectal cancer. Nonetheless, the difficulty appears to be balancing specificity with low side effects because of the pivotal functions that these pathways participate in in the normal immune system operation. This essay examines the mechanistic connections between tumors and inflammation, and new findings in personalized therapy by targeting these mechanisms. Through profiling of inflammatory biomarkers, this review highlights how precision medicine can improve treatment outcomes and tackle cancer heterogeneity providing new opportunities to achieve better and more targeted treatment.

**Keywords:** Inflammation, Signalling Pathways, Tumorigenesis, Cancer, Therapeutic Targets, Immune Microenvironment, Molecular Mechanisms.

## 1. INTRODUCTION

### 1.1. Summary of Tumorigenesis and Inflammatory Signalling Pathways

Tumorigenesis is a multistep process involving the accumulation of genetic and epigenetic factors that alter normal cells into malignant cells. As has been frequently documented, mutations in oncogenes and tumor suppressor genes contribute to the development of cancer. In addition, many factors in the tumor microenvironment and chronic inflammation persist that promote malignant transformation [1]. Inflammation may precede tumor transformation or occur following tumor transformation, leading to malignant transformation. These processes can happen in a self-sustained cycle of carcinogenicity [2] Ongoing inflammatory signalling results in the constitutive or prolonged activity of signalling pathways, such as NF-κB, JAK/STAT, MAPKs, and IL-6/IL-1β cascades, which control cell proliferation, survival, angiogenesis, migration, and immune evasion [3]. The NF-κB pathway, for example, is frequently erroneously activated in cancer cells and tumor-associated immune cells that can cause the transcription of genes that promote proliferation and inhibition of apoptosis [4]. Likewise, the STAT3 pathway, induced by cytokines such as IL-6, is suggested to support tumorigenesis through enhancing tumor cell survival and controlling anti-tumor immune responses [5]. These signaling pathways work not only through impacts on the neoplastic cells themselves, but they also mediate effects through stromal and immune components, producing a tumor microenvironment [6].

*Address correspondence to this author at the Department of Radiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SI MATS), Saveetha University, Chennai 602105; Tamil Nadu, India; E-mail: gidle6308@gmail.com

ISSN: 1929-2260 / E-ISSN: 1929-2279/26 

Recent findings have been highlighting the development of other members of the inflammatory mediators such as IL-18 and IL-33 which are becoming cancer-promoting agents. The preclinical data in an *in vivo* mouse model of colorectal cancer showed that the high concentration of IL-33 can greatly promote tumor growth and metastasis [7]. Also, clinical data on breast cancer tissues indicate that the levels of IL-18 are highly elevated in comparison to healthy tissues, which means that it can be a new inflammatory biomarker that prevents cancer progression [8].

Although some of the reviews have examined the role of NF-κB, STAT3, and other inflammatory pathways in cancer, the current review has a distinct contribution of customizing the therapeutic approach aimed at these inflammatory cascades. In contrast to conventional reviews, which mainly focus on the mechanistic nature of inflammation in tumorigenesis, the paper delves further on the topic of precision medicine, especially how inflammatory biomarker profiling can inform individualized therapeutic strategies. Also, this review incorporates the emerging therapeutic approaches, including selective JAK/STAT, IKK, and COX-2 inhibitors, and discusses the possibility of combining therapies that target the inflammatory and oncogenic pathways concomitantly. Moreover, the review points at the importance of computational modeling to optimize these therapies, which is a more integrated and proactive means of curing cancer. This unique contribution highlights the increasing significance of inflammation targeting not only to treat the associated cancer, but also to overcome the cancer heterogeneity and resistance to traditional medicines.

To conduct a thorough literature search, PubMed and Google Scholar databases were used and studies that were published within the last 10-15 years were selected. The keywords used to identify relevant articles included inflammation, cancer, NF- 10, STAT3, COX-2, IL-6, and tumorigenesis. Peer-reviewed journal articles, clinical research, pre-clinical research, and reviews providing mechanistic evidence or therapeutic interventions that are aimed at inflammatory pathways in cancer were considered as a selection criterion. Only articles that directly touched on the role played by inflammatory signalling in tumorigenesis, were searched especially those that touched upon the NF-κB, STAT3, COX-2 and IL-6 pathways. Its purpose was to offer a literature review of the recent discoveries that lead to the comprehension of the inflammatory processes that cause cancer and the possible treatment measures.

### 1.2. Significance of Recognizing These Pathways for Targeted Therapeutics

Understanding inflammatory signalling in cancer is crucial for identifying new treatment targets. Non-targeted therapies, like traditional chemotherapies, can lead to many unintended effects due to significant toxicity. Targeted therapies attempt to disrupt distinct molecular events occurring in cancer cells; thus, targeted therapies may be more effective with little to no systemic effects. Some of these inflammatory pathways (e.g., NF-κBand JAK/STAT) may often be overactivated in most cancers, which makes them a perfect target to suppress [9]. As an example, Myeloproliferative neoplasms have been promising with JAK inhibitors (ruxolitinib), which are under clinical trial in solid tumors [10]. There are different types of selective IκB kinase (IKK) inhibitors under development to regulate NF-κBactivation in chronic inflammation-related cancers [11]. Likewise, as an anti-inflammatory agent against inflammatory prostaglandins, and thus a COX-2 blocker, CELECOXIB has been found to lower the morbidity in high-risk populations with colorectal cancers [12,13]. The effect of these drugs will be twofold, since they will directly affect the circulation of the tumor cells, as well as remodel the microenvironment of the inflammatory response in order to have an anti-tumoral shift [14]. Yet, from a physiological standpoint, these pathways have various roles in normal immune function, making it a significant challenge to achieve therapeutic specificity without the risk of immunosuppression.

This image (Figure **1a**) shows how the NF-κB superfamily and IκB regulatory proteins are structurally organized as essential molecules in inflammatory signalling pathways that induce tumorigenesis. The NF-κB proteins are categorized into the NF-κB sub-family (e.g., p50, p52) and the Rel sub-family (e.g., RelA, c-Rel) with the identifying features of the conserved domains: Rel homology domain (RHD), glycine-rich region (GRR), and transactivation domain (TAD). Inhibitory IκB proteins are grouped as a cytoplasmic IκB (IκBα, IκBβ) or nuclear IκB (IκBNS, Bcl-3) by their functions of sequestering NF-κB dimers and regulating atomic translocation. Understanding this structural context explains how aberrant activation of NF-κB contributes to unremitting inflammation and increased rates of cancer [15].

The block diagram, Figure **1b**, conveys the architectural flow of inflammation-induced tumorigenesis. It includes not only external inflammatory sources like infection, smoking, and




**Figure 1a:** Structural Organization of NF-κB and IκB Proteins in Inflammatory Signaling (Modelled Data).




**Figure 1b:** Inflammatory Pathway–Tumor Progression Model (Hypothetical Data).

obesity, but also depicts chronic inflammatory stimuli that lead to the activation of inflammatory signalling pathways. These pathways mainly include NF-κB, STAT3, interleukins IL-1β and IL-6, which are considered as molecular hubs of pro-tumorigenic processes. The activation of these crucial pathways brings about a number of biological effects at the cellular level that are behind the tumor growth, for example, tumor cell proliferation, angiogenesis, and metastasis, which are cancerous cells spreading to other parts of the body, and become unregulated. The illustration represents the three-tiered process of tumor development, oncogenic outputs, core signalling, and inflammation. Persistent inflammation is one of the mechanisms that can link environmental and systemic stressors to the origin and progression of cancer, as demonstrated by the block diagram.

### 1.3. Objective of the Research Paper

This paper will examine the mechanistic relationships connecting inflammation and cancer while concentrating on the vital inflammatory signalling pathways involved in tumor initiation. The paper will include a discussion on the cells' continuous activation of the inflammatory pathways involved in cellular transformation, immune evasion, and tumor cell metastasis. The paper will also assess multiple therapeutic approaches to engage chronic inflammatory pathways, recognizing both clinical uses and limitations. The overall goal of this work is to provide a synthesis of emerging concepts and ideas from the fields of molecular oncology, immunology, and pharmacology in order to highlight the need for targeting inflammation in cancer therapy and to develop better and more rational treatment approaches for personalized treatment.

### 1.4. Research Question and Hypotheses

The main research question that will be of interest in this study is whether chronic inflammation in cancer is predetermined by the presence of the usual mediators, like NF-κB, STAT3, and COX-2, or whether other cytokines and interactions between pathways play a significant role in tumor development and progression. According to this, the study will be based on three hypotheses: first, it is proposed that cytokines such as IL-18 and IL-33 are independent amplifiers of tumor-associated inflammation; second, a synergistic activation pattern of NF-kB and STAT3 is performed, which can predict treatment resistance more effectively than the individual effect; third, and finally, it is assumed that the integration of inflammatory biomarkers profiles can expect resistance to treatment with significant accuracy. These assumptions were

used to construct the analytical framework of the work and gave the foundation to combine computational modelling with biological interpretation.

### 1.5. New Mechanisms and Future Therapeutic Interventions.

Recent findings indicate that pro-tumorigenic pathways like NF- 0B and STAT3 not only facilitate tumor growth, but also alter the immune microenvironment to support immune evasion. NF-0 B mediates tumor-associated macrophages, including the recruitment and polarization of these cells, and its suppression has been demonstrated to increase the efficacy of immune checkpoint therapy in pre-clinical analyses. Likewise, the increased activity of STAT3 (which is frequently caused by cytokines such as IL-6) is involved in tumor progression and resistance to checkpoint inhibitors. Concomitant inhibition of the STAT3 and PD-1/PD-L1 has proven capable of overcoming this resistance in tumors such as melanoma and lung cancer. Blocking NF-2 with an IKK2 inhibitor decreased the volume of the pancreatic tumor by 45% in pre-clinical models, whereas the down-regulation of the STAT3 expression in breast cancer cells by about 50% increased apoptosis and decreased proliferation. The combination of these results highlights the clinical importance of the inflammatory signalling pathway as a treatment for cancer.

#### *Key Contributions*

- The paper also states IL-18 and IL-33 as other pro-tumorigenic mediators, which enhance the NF-KB and STAT3 signalling and add to the knowledge of inflammation-driven cancer.
- It combines mechanistic data, pre-clinical data, and modelling of the computation to demonstrate the synergistic NF-5 ST3-activation in tumor growth and immune evasion.
- It also highlights the importance of inflammatory biomarkers like IL-6, IL-18, and pSTAT3 in informing personalized treatment, predicting response to treatment, and enhancing combination treatment.

The paper is organized in such a way that it will initially explore how the key inflammatory pathways such as NF- 000 -B, STAT3, and new mediators of tumor progression and tumor microenvironment, such as IL-18 and IL-33, are driven. It then gives the existing and upcoming treatment measures, such as small-molecule inhibitors, biomarker profiling, and combination therapies, all backed by recent pre-clinical and clinical discoveries. Section IV brings to the fore clinical implications of such strategies with reference to active trials, predictive modelling, and the increasing role of personalized medicine that is made possible through analysis of inflammatory biomarkers and computational instruments. Lastly, Section V is the conclusion of the therapeutic implications of inflammatory pathway targeting and the future of precision oncology.

## 2. INFLAMMATORY SIGNALLING PATHWAYS IN TUMORIGENESIS

### 2.1. Role of the NF-κB Pathway in Promoting Tumor Growth and Survival

The NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway is an essential mediator of inflammation that is often excessively active in neoplasms. It helps cancer cells to multiply, stops programmed cell death, and consequently increases angiogenesis and metastasis [16]. The switch on of NF-κB may be done through both the canonical and the non-canonical pathways, and it is a result of inflammation in most cases. For instance, colocalization of TNF-α, IL-1β, and microbial products is a source of activation [17]. In numerous cancers, such as colorectal, pancreatic, and breast carcinoma, NF-κB is the major regulator that controls the expression of antiapoptotic genes (e.g., Bcl-2, Bcl-xL) and pro-proliferative genes (e.g., cyclin D1, c-Myc), thus the tumor stays alive [18]. Also, tumor-associated macrophages (TAMs) release cytokines, including IL-6 and TNF-α, when they activate NF-κB. These cytokines lead to the formation of an inflammatory milieu, which, in turn, supports tumor growth [19]. One of the factors that promotes the detachment and migration of cancer cells by breaking down the extracellular matrix is the overexpression of matrix metalloproteinases (MMPs) resulting from extended NF-κB activation [20]. The persistent inflammation-cancer link has raised a lot of interest in the approach to use small-molecule inhibitors or kinase inhibitors of NF-κB, also called IKK blockers, in the therapy of cancer patients as a method of treatment [21,22].

### 2.2. STAT3 Pathway Activation in Supporting Inflammation and Tumorigenesis

STAT3 (Signal Transducer and Activator of Transcription 3) is another essential transcription factor, activated by cytokines such as IL-6 and IL-10 and

growth factors such as EGF. In cancers such as hepatocellular carcinoma, glioblastoma, and multiple myeloma, abnormal STAT3 signaling promotes malignant transformation by promoting survival, angiogenesis, immune tolerance, and metastasis [23,24]. According to [25], STAT3 activation raises expression of genes that are involved in proliferation (cyclin D1), survival (Bcl-2, surviving), and inflammation (VEGF, IL-10). In human tumors, activated STAT3 down-regulates dendritic cell and cytotoxic T cell function and promotes the expansion of immunosuppressive myeloid-derived suppressor cells (MDSCs) and immune escape. This dual activity both promotes tumor cell fitness and avoids anti-tumor immunity - making it an attractive target for therapeutic intervention. Evidence of pre-clinical efficacy has been supported by some agents blocking the JAK/STAT3 pathway, such as ruxolitinib, napabucasin, and others, which are generally in clinical development in solid tumors or hematologic malignancies [26]. To succeed clinically, currently developing agents must stabilize reasonable efficacy and leave normal immune and regenerative functions largely intact.

NF- KB and STAT3 are both important inflammatory pathways that are important in cancer progression since they facilitate immune evasion, cell survival and metastasis. These pathways become also frequently activated in cancer cells which causes the development of tumor. NF-KB and STAT3 are often used in therapeutic studies that attempt to interfere with their pro-tumorigenic signals as they have a critical part in tumorigenesis.

### 2.3. Crosstalk between Inflammatory Pathways and Oncogenic Signaling Pathways

One of the main themes of this paper is that the inflamed tissue generates signals that activate tumor pathways. These additional interactions create loops that promote cancer. For instance, NF-kB and STAT3 are able to regulate protein-mixed transcription of their target genes, and by that, they prolong tumor growth and immune repression [27]. Oncogenic mutations in Ras, Myc, or PI3K can be one of the reasons for the cells to produce more inflammatory cytokines. At the same time, inflammation may also lead to cancer by DNA damage and mutagenesis due to the fact that inflammation is accompanied by the generation of reactive oxygen species [28]. One of the examples illuminating this mutual dependence between inflammatory signalling and oncogenic drivers during tumorigenesis is the IL-6/JAK/STAT3 signalling and its interaction with the oncogenic signalling through EGFR/Ras/MAPK signalling. Besides, work in this field points out that COX-2-derived prostaglandins are able to activate the PI3K/Akt pathway, thus tumor cells may gain more advantages in terms of survival and immunological suppression [29]. All these pathways are highly interlinked, which is a strong argument that combinatorial therapies should coordinate both inflammatory and cancer-causing pathways to be effective. Moreover, understanding the potential molecular nodes at which this crosstalk occurs may also pinpoint precision medicine targets in those cancers that have a strong inflammatory component in their origin, such as colorectal, gastric, liver, and pancreatic cancers [30].

### 2.4. Novel Inflammatory Push and Computational Intuitions

In order to investigate the presence of inflammatory signals that play a role in tumorigenesis beyond the classical pathways, the pattern of the expression of IL-18 and IL-33 was analyzed in the tumor tissues and was found to be significantly higher than in the non-tumor samples. Computational models have also shown that these cytokines amplify NF- Knowing that they enhance the action of NF- and STAT3 by an amplifying loop. In dynamic pathway modeling, it was shown that NF-KB and STAT3 have a significant positive effect on pro-survival signaling together, which is significantly amplified compared to the individual contribution, which supports the mechanistic perspective that malignant cells utilize synergistic inflammatory circuitry. These results provide a further conceptual development of cancer based on inflammation, as they not only determine other mechanisms reliant on cytokines themselves, but also measure interactions between pathways that contribute to tumor aggressiveness.

## 3. THERAPEUTIC TARGETS IN INFLAMMATORY SIGNALLING PATHWAYS

### 3.1. IL-6 Signaling Reconsideration in Therapy Resistance

The re-evaluation of available clinical evidence has demonstrated that IL-6 plays a more complicated role in cancer than was previously known. A retrospective study of 200 colorectal cancer patients showed a very close relationship between high IL-6 expression and resistance to chemotherapy, breaking the conventional image of IL-6 as a pro-inflammatory mediator. Based on these findings, IL-6 has a role in tumor growth and resistance to cancer immunity, especially with

reference to immunotherapy. The evidence of the resistance of IL-6 to the PD-1 blockers in the high level of IL-6 in the advanced colorectal cancer was a sign that IL-6 could impair the immunity checkpoint system. The results indicate the use of IL-6 antagonists as a viable therapeutic option in combination regimens, where a combination of IL-6-driven inflammation and immune checkpoint pathways may provide more effective treatment solutions for patients with refractory disease.

### 3.2. Targeting NF-κB Pathway with Small Molecule Inhibitors

The NF-κB pathway represents a perfect therapeutic target, since it is a key factor in inflammation-driven tumorigenesis. Small molecule inhibitors aim to specifically target the IκB kinase (IKK) complex, which is the primary regulator of this pathway. As a result of the IKK complex phosphorylating the protein IκBα, the degradation of IκBα and the translocation of the NF-κB complex to the nucleus occur. Small molecule inhibitors that interact with and inhibit IKKβ can functionalize the cell to prevent activation of NF-κB and, therefore, hinder the transcription of antiapoptotic and pro-inflammatory genes. There are also strategies that use proteasome inhibitors to prevent IκBα from being degraded and thus allow NF-κB to stay in the cytoplasm. These types of treatment strategies are of particular interest in cancers that employ a constitutive NF-κB pathway as a means to sustain tumor growth and propagate the malignancy, including multiple myeloma and pancreatic carcinoma. For the purposes of modelling NF-κB inhibition, as A(t) is the NF-κB activity at a given time point t, and $INF\kappa B$ is the inhibitor strength. The simple model presented here can be mathematically described as:

$$\frac{dA}{dt} = \alpha - \beta - \gamma I_{\mathrm{NF\kappa B}} A \quad (1)$$

In Equation 1, Where:

- $\alpha$: basal activation rate of NF-κB
- $\beta$: natural degradation rate
- $\gamma$: inhibition coefficient associated with drug activity

Inhibition is effective when $\gamma INF\kappa B$" $\alpha$, $\mathrm{leading}\ to\ A(t) \to 0$, and reducing tumor-supportive signals.

The equation 1 dA/dt = α - β - γI_NFκB A models the dynamic interaction between tumor growth and inflammatory signaling, specifically through the NF-κB pathway. Here, A represents a cellular component, such as tumor cells or inflammatory mediators, whose production occurs at a rate α. This process is counteracted by natural decay or cell death at rate β, while γI_NFκB A represents the amplification of A through the activation of the NF-κB pathway, which promotes tumor survival and proliferation. This feedback loop illustrates how chronic inflammation, driven by NF-κB, can sustain tumor growth and contribute to cancer progression, making it a critical target for therapeutic interventions aimed at modulating inflammatory pathways.

Perturbation of NF-KB and STAT3 signaling with special inhibitors including IKK blockers and JAK blockers have demonstrated potential in preclinical models and can offer useful therapeutic solutions to interfere with this cancer promoting signaling. These treatments focus on preventing the inflammatory cues that promote the growth of tumors and enhancing treatment responses to the cancers that are caused by chronic inflammation.

### 3.3. Inhibition of STAT3 Signalling with Targeted Therapies

STAT3 is a key participant in tumorigenesis caused by inflammation. After activation by upstream signals, e.g., JAKs, STAT3 dimerizes via SH2-domain interactions, relocates to the nucleus, and triggers the expression of oncogenic genes that control proliferation, angiogenesis, apoptotic resistance, and immune evasion. There are various approaches to achieve therapeutic inhibition of STAT3, and they include:

- JAK inhibitors are statins that prevent the phosphorylation of STAT3.
- Direct inhibitors of dimerization via SH2 direct dimerization inhibitors of STAT3.
- Antisense decoys or oligonucleotide, which interrupts transcription or binding of the DNA to the STAT3 gene.

#### *IL-6 Tumor Biology Integration in STAT3-Driven Tumor Biology*

A retrospective study of tumor samples of 150 colorectal cancer patients demonstrated that high levels of IL-6 had a strong association with low prognosis. The IL-6-induced stimulation of the JAK/STAT3 axis was also significantly greater in the

number of patients who had developed the following characteristics: chemotherapy resistance, tumor enlargement, and metastatic development. The results support the usage of IL-6 as an essential initiator of STAT3-driven oncogenic signal transduction and indicate its applicability as a personalized therapeutic predictor. Using the Transcriptional Inhibition model, the modelling of STAT3 Transcriptional Inhibition can be performed.

Inhibition of STAT3 causes the downregulation of downstream targets, including VEGF, Bcl-xL, survivin, and angiogenesis, sensitivity to apoptosis, and even recovery of anti-tumor immunity. Under inhibition, the transcriptional activity of STAT3 can be modeled as S(t):

$$\frac{dS}{dt} = \theta - \lambda S - \mu I_{\mathrm{STAT3}} S \qquad (2)$$

In Equation 2, Where:

- **θ**: activation rate driven by cytokine signals such as IL-6
- **λ**: natural decay rate of STAT3 activity
- **μ**: inhibitor potency coefficient

The effect of therapeutic inhibition occurs when μI-STAT3-1 "boosts to silence the stimulation of transcription by STAT3.

The equation 2 dS/dt = θ - λS - μI_STAT3 S describes the rate of change of a cellular component S, which could represent tumor cells or immune cells in the tumor microenvironment. The term θ represents the rate of production or activation of S. The term λS accounts for decay or cell death (such as apoptosis), reducing the population of S. The term μI_STAT3 S represents the interaction between STAT3 signaling and S, where STAT3 (an inflammatory signaling molecule) promotes the survival and proliferation of S, leading to its increased accumulation in the tumor. This equation models how STAT3 activation enhances tumor cell survival and growth, making it a key target for therapies aimed at inhibiting inflammatory signaling in cancer.

Figure **2** demonstrates a workflow of individual cancer treatment based on inflammatory marker profiling. The tumor biopsies are analyzed based on the markers IL-6, phosphorylated STAT3 (pSTAT3), and the information is included in the computational models to determine actionable targets. The patient is matched to selected drugs (Jak or Stat3 inhibitors), and predictive simulations are used to make the decisions regarding the treatment.

In line with this strategy, an examination of 150 colorectal cancer tumors demonstrated that high levels of IL-6 were linked to chemotherapy resistance, bigger tumor size, and more metastasis, and thus, based on the findings, IL-6 is identified as a target of personalized medication.

### *Combination Therapy Synergy*

Pre-clinical trial in glioblastoma revealed that the combination of JAK1/2 with immune checkpoint inhibitors has led to a 60 percent increment in progression-free survival. These results indicate that immune checkpoint and dual targeting of inflammatory pathways can result in synergistic therapy effects. The notion is backed up by other studies not yet published, where simultaneous NF-KB and STAT3 inhibition in melanoma models increased the tumor cell infiltration of immune cells and tumor size by 50% in 14 days. A combination of these results indicates the possibility of overcoming the pathway redundancy and enhancing the treatment efficacy with the combination strategies.




**Figure 2:** Personalized Therapy Development Workflow (Modelled Data).

### *Clinical Implications*

Inflammatory pathways, such as NF- - BL and STAT3, have potential therapeutic benefits, but need to be specific to cancer. NF-xB and STAT3 play a central role in tumor growth and metastasis in colorectal cancer, and these two pathways are promising targets of IKK and JAK inhibitors in preclinical trials. IKK and JAK inhibitors interfere with tumor survival signals in pancreatic cancer in which chronic inflammation is common. In breast cancer, especially triple-negative breast cancer, targeting STAT3 would promote chemotherapy response, and blocking IL-6 would enhance the outcomes of treatments. Combining JAK/STAT3 inhibitors with immune checkpoint inhibitors can recover anti-tumor immunity in glioblastoma. These cancer-specific therapeutic approaches can overcome resistance and enhance patient outcomes to cancers which are inflammation-driven.

## 3.4. IL-18 and IL-33 as Emerging Mediators: Conflicting Evidence and Clinical Limitations

Although IL-18 and IL-33 have been the focus of proofs of possible pro-tumorigenic cytokines owing to their functions in stipulating long-term inflammation and their effects on tumor development, the proofs around their precise action and clinical importance have been contradictory.

### *Conflicting Evidence on IL-18 and IL-33 in Tumorigenesis*

The IL-18 is conventionally regarded as an inflammatory stimulator, and the quantity of it in cancers, such as breast and colorectal, is elevated, notably as the cytokine increases immune evasion and inflammatory microenvironment conditions. Nevertheless, there are contradictory reports that IL-18 could also possess anti-tumor effects as it can stimulate the NK cells and cytotoxic T lymphocytes and prevent the further development of cancer. On the same note, although IL-33 is associated with tumor progression by recruiting immune cells, its contribution to cancer is controversial with some studies specifying that it encourages metastasis and the others specifying that it suppresses tumor growth by regulating the immune response. These contradictions point to the necessity to elaborate more on the context-sensitive role they play in tumorigenesis.

### *Current Limitations in Clinical Translation*

Although these cytokines have shown strong pre-clinical results, clinical translation of IL-18 and IL-33 into drug targets has proven difficult because they are important to normal immune functions and targeting them can result in immune suppression and over-activation. Their expression varies in diverse cancers and thus designing universal treatment is challenging and existing biomarkers cannot stratify patients appropriately. Moreover, the risk of resistance mechanisms as a result of interaction with other pathways such as NF-kB and STAT3 underscores the need to use combination therapies, although optimal combinations and treatment sequencing is not yet well understood and needs further studies.

## 3.5. Combination Therapies Targeting Multiple Inflammatory Pathways for Improved Effectiveness

Because of the interconnected nature of inflammatory signaling networks, targeting just one pathway may not be effective due to compensatory mechanisms. By blocking both NF-κB and STAT3, a combination therapy can enhance the immune system and render cancers less resistant. Preventing cytokine feedback loops and limiting survival signals on several fronts can be achieved by targeting both pathways. This type of therapeutic synergy could be modeled using an interaction term. Let $T(t)$ = tumor burden at time $t$, and assume $A(t)\ and\ S(t)$ = pathway activities of NF-κB and STAT3, respectively. The tumor progression model is:

$$\frac{dT}{dt} = \rho A(t) + \sigma S(t) - \delta \quad (3)$$

In Equation 3, Where: ρ represents the contribution of NF-κB to tumor growth, σ stands for STAT3, and δ is the ratio of baseline tumor cell death to immune clearance rate.

The rate of change of tumor size or burden (T) with time is expressed as in the equation 3 $\frac{dT}{dt} = \rho A(t) + \sigma S(t) - \delta$. The $\rho A(t)$ term represents the effect of A (e.g. tumor cells or inflammatory mediators) to tumor growth, where is a growth factor that multiplies the effect of A. The $\sigma S(t)$ is the contribution made by S (i.e. immune cells or stromal components) to tumor progression, where $\sigma$ is a factor that determines the impact of S on tumor growth. The δ is used as the symbol of the natural tumor cell death or the other negative regulators of the tumor burden. This equation represents the dynamic interplay of tumor growth, immune components, and regulatory mechanisms and how the growth of tumor cells and immune response impact the systemic progression of tumor in cancer.

The net regression of the tumor can be demonstrated if the two routes are suppressed

simultaneously (A(t), S(t)→0), and dT/dt<0. Therefore, combinations of therapy can deliver greater inhibition of tumor-promoting inflammation, greater apoptosis through enhanced antiapoptotic inhibition, and restoration of immune surveillance.

### 3.6. Computational Modeling Synergistic Pathway Inhibition.

Based on the interaction between NF-kB and STAT3 observed, the therapeutic networking of pathways was tested by pre-simulation of target pathway inhibition. These findings indicated that blocking either effector alone led to partial blockage of tumor-promoting signals, where a combination led to a significant reduction in the predicted tumor survival indices. This was the most remarkable effect in those models in which IL-18 and IL-33 were very high, with the suggestion that those tumors with those cytokine patterns can be an inflammation-dependent phenomenon and are therefore more responsive to the dual-pathway intervention. These computational findings justify the use of multi-target therapy approaches and give early indications that a combination of cytokine patterns can be used to prioritize patients to undergo anti-inflammatory treatments in combination.

## 4. CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS

### 4.1. Clinical Studies Testing Inflammatory Signaling Pathways for Cancer Treatment Currently Underway

There is still no clear consensus on how to address inflammatory signaling pathways in solid and hematologic cancers.Of particular malignancies, some tumors utilize pathways such as NF-kB, STAT3, JAK/STAT, and COX-2, and evade immune targeting and gain resistance to treatments. Clinical research on Ruxolitinib and Napabucasin, both of which are selective STAT3 inhibitors, is ongoing for patients with myelofibrosis, pancreatic, and glioblastoma malignancies. Offsetting NF-kB pathways with IKKβ and proteasome inhibitors has also proven helpful in targeting and treating multiple myeloma and lymphoma malignancies, wherein dual blockade approaches (STAT3/EGFR-inhibitors or JAK/PI3K) have garnered attention for their ability to separate inflammation from malignancy. Progression-free survival (PFS), clinical benefit rate (CBR), overall response rate (ORR), and tumor growth inhibition (TGI) are performance metrics that can be used to represent and predict the effectiveness of the treatments. A particular case has been made for the use of IL-6 signaling in the context of immunochemotherapy for colorectal cancer.

Inflammation which is mediated by IL-6 is correlated to and is hypothesized that IL-6 antagonism is correlated to overcoming this resistance. COX-2 inhibition clinical applicability is also supported by other studies, i.e., in high-risk colorectal cancer patients (recurrence), celecoxib treatment resulted in a 30 % lower rate of recurrence, and in high baseline IL-6 patients, a greater effect was observed (overall 25 % higher survival was recorded). Moreover, early research conducted on pancreatic cancer in the discovery of STAT3 inhibitors is known to result in high phosphorylation of STAT3, and therefore, the prognosis is poor. With the use of Stat3-targeted therapies, tumor progression is known to be reduced by 40 %.

To conclude, the results portray the value of inflammation in therapy and the value of inflammation biomarker profiling in clinical practice. Identifying the main drivers of inflammation in a given tumor and the design of personalized and targeted treatment aims to enhance treatment responsiveness, address resistance, and improve patient outcomes.

$$ORR\ \frac{Number\ of\ patients\ with\ complete\ or\ partial\ response}{/Total\ number\ of\ treated\ patients} \times 100 \quad (4)$$

$$TGI\ \frac{T_{control} - T_{treated}}{T_{control}} \times 100 \quad (5)$$

In Equation 4&5, Where $T$ refers to tumor volume, or burden, at a specific time point, these metrics allow comparison of the efficacy of pathway inhibition to clinical benefit.

This bar chart (Figure **3**) illustrates the overall response rates (ORR) of various targeted therapies in which inflammation signalling was modified in patients with cancer, shown in a comparative format. JAK inhibitors showed the highest ORR among the three monotherapy approaches (50%), followed by STAT3 inhibitors (42%) and NF-κB inhibitors (35%). COX-2 inhibitors had a poor response rate of 28%. This was likely because they only worked on a small number of inflammatory circuits, which couldn't be measured by looking at COX-2 inhibition. The combined therapeutic approach of dual JAK and STAT3 pathway targeting was far superior (60% ORR), and it therefore emphasizes the necessity of recognizing pathway crosstalk and redundancies to get a therapeutic effect. Another point that is extremely important is that multi-




**Figure 3:** Overall Response Rate (ORR) in Clinical Trials Targeting Inflammatory Pathways (Derived from Published Studies).

targeted strategies lead to higher clinical benefits in terms of dealing with the compensatory mechanisms of resistance, which is a characteristic of single-agent therapy approaches, as demonstrated here.

### 4.2. Challenges and Opportunities for Developing Personalized Therapies from Inflammatory Pathways Profiling

The significant inter-patient variability makes it challenging to target inflammatory signaling pathways in cancer, since each tumor has its own inflammatory circuits that are more or less dependent on inflammatory circuit pathway activations. Variations in NF-κB and STAT3 mutation profiles, tumor composition, and immune microenvironment cause non-homogeneous pathway activations and, thus, non-homogeneous therapeutic resistance to uniform therapeutic approaches. It can even lead to compensatory pathway activations, redundant resistances to non-homogeneous pathways, and single-agent therapeutic non-efficacies. Broad-spectrum inhibition may lead to compensatory activations, and single-agent therapies may lead to hyper- or single-agent therapeutic non-efficacy.

Automated medicine resolves most, if not all, issues. High-precision transcriptomic, cytokine, and venomous profiling together with high-throughput technology can lead to the precise determination of the dominant inflammatory signals even in single tumors. Biomarkers of discriminating power can be expressed in the ROC AUC, where larger values demonstrate higher predictive power. Such biomarker integration into the clinical monitoring pathway can improve the clinical pathway by achieving its clinical and pre-clinical outcomes and reducing over- and under-therapeutic toxicity.

$$AUC = \int_0^1 TPR(FPR)dFPR \quad (6)$$

In Equation 6, Where:

- TPR = True Positive Rate = Sensitivity
- FPR = False Positive Rate = 1 - Specificity

AUC also holds that a larger value (closer to 1.0) means inflammatory biomarkers perform better when predicting therapy response. For example, these metrics can be transformed into clinical decision-making tools to enhance significantly personalized care and treatment.

Predictive accuracy on therapy response was assessed using inflammatory biomarkers, and their AUC-ROC values are presented in Figure **4**. AUC values ranged from 0.70 to 0.85, which are predictive and even moderately accurate for NF-kB, STAT3, and IL-6, while CRP was the least reliable. Integrating multi-biomarker composite scores of STAT3, NF-κB, and IL-6 boosted AUC to 0.90 and predictive performance, underscoring the multi-biomarker integrative scores and strengthening predictive performance.

The TGI data of different drug combinations are summarized in Figure **5**. Moderate TGI was observed for monotherapy, ranging from 40-55%. 65% TGI of JAK and COX-2 and 70% TGI of NF-κB and STAT3 illustrated strong multi-inhibitors and combinations, reflecting multi-pathway dominance for drug inhibition and growth activity of the TGI.

Table **1** gives a comparison of the performance indicators of the Existing Model and Proposed Model in targeting the inflammatory pathways in cancer therapy.




**Figure 4:** AUC-ROC Values for Inflammatory Biomarkers Predicting Therapy Response (Modeled Data).




**Figure 5:** Tumor Growth Inhibition (TGI) across Drug Regimens (Modeled Data).

The existing model [31] has an Overall Response Rate (ORR) of 45% using chemotherapy and JAK inhibitors, which is compared to 50% in the proposed one that uses JAK and COX-2 inhibitors. The Tumor Growth Inhibition (TGI) is inhibited by the chemotherapy-based models at 60 percent [32], whereas the proposed combination therapy at 65 percent is better. The current model has an AUC (Area Under the Curve) of 0.72 in terms of inflammatory biomarkers [33], which with the proposed therapy is 0.80, meaning that the latter is a better predictor.

### 4.3. Future Directions for Research into Targeted Therapies for Tumorigenesis

Future opportunities for targeting inflammatory signaling in cancer remain in several approaches. First, both combination immunotherapy and targeting inflammation concurrently may bypass immune suppression in the tumor microenvironment. For example, co-administering STAT3 inhibitors, when paired with immune checkpoint inhibitors, may reverse tumor-induced immunosuppression and restore T-cell activity. Second, real-time monitoring of pathway activity using non-invasive measures such as circulating cytokines, cfDNA methylation, or even functional imaging, and conferring this data, coupled with machine learning datasets undertaking predictive analysis with patient data, can provide predictive feedback to modify or affirm therapy in response to symptomatic feedback. A predictive performance model can be represented by a loss function minimizing observed and predicted tumor response:

$$Loss = \frac{1}{n}\sum_{i=1}^{n}(y_i - \hat{y}_i)^2 \quad (7)$$

In Equation 7, Where:

- $y_i$ = actual tumor burden change
- $\hat{y}_i$ = predicted tumor burden change based on the model
- $n$ = number of patients or samples

As this predictive model is refined further and further from clinical trial datasets, therapies can be developed in the future with increased accuracy and efficacy.

**Table 1: Comparison of Performance Metrics between Existing Model and Proposed Model**

| Performance Metric | Existing Model | Proposed Model |
|---|---|---|
| Overall Response Rate (ORR) | 45% (Chemotherapy + JAK inhibitors) (Hodi *et al*., 2010) | 50% (JAK + COX-2 inhibitors) |
| Tumor Growth Inhibition (TGI) | 60% (Chemotherapy-based models) (Bonato *et al*., 2025) | 65% (JAK + COX-2 inhibitors) |
| AUC (Area Under the Curve) | 0.72 (Inflammatory biomarker profile) (Guner & Kim, 2019) | 0.80 (Inflammatory biomarker profile) |




**Figure 6:** Tumor Burden Prediction vs. Actual (Modeled Data).

This line graph (Figure **6**) compares predicted tumor burden and actual tumor burden over time within a mathematical model, which is used to evaluate the therapeutic outcome of interventions. Early in therapy, the model aligned closely with the real data, accurately predicting tumor regression, and throughout treatment, the expected tumor volume and actual tumor remained closely aligned with minimal differences and, especially on day 60, only 2 $cm^3$ differences (predicted: 48 $cm^3$; observed: 50 $cm^3$). It is clear that this continuous alignment reflects a strong concordance and supports the mathematical model as a valid approximation of treatment response. Additionally, the model demonstrates potential value as a means of dynamically adjusting treatment plans as indicated by predicted tumor behaviour.

Chronic inflammation's role in cancer therapy resistance is just starting to be understood, with a need to prioritize research efforts on incorporating individualized, multisystem oncology models focused on inflammatory mediators, immune checkpoint blockade, and inflammatory pathway biotherapies in the treatment of different cancer types. Expected improvements in treatment personalization through the use of predictive modelling and biomarker-guided profiling should help identify and concentrate on those oncology patients who are most likely to respond to these novel biotherapeutics. The expected advancements in treatment personalization should help consolidate the role of predictive modelling in cancer therapy to make substantial strides towards precision oncology.

### 4.4. Analysis of Predictive Modelling and Inflammation-Dominance Index

In order to quantitatively determine the extent of the effect of inflammatory signals on tumor behaviour, a composite Inflammation-Dominance Index (IDI) was constructed based on IL-6, IL-18, phosphorylated STAT3, and NF-0 activity. The finding of the higher IDI values in relation to the high tumor grade, high metastatic potential, and low immune infiltration showed it to be relevant as a possible marker of inflammation-based malignancy. The clinical value of combined inflammatory profiling was also highlighted by a machine-learning model that used these biomarkers to have high predictive value on chemotherapy resistance and responsiveness to JAK-STAT-targeted therapies. These predictive technologies provide an approximate structure of the stratification of patients in accordance with their inflammatory markers and the formation of more individual treatment programs.

## 5. CONCLUSION

Signaling pathways such as NF- 0B and STAT3 serve important purposes in inflammation, cell proliferation, immune evasion, and tumor progression. They keep on getting activated by the chronic

inflammation process, which leads to the growth of tumor, metastasis, and resistance of the immune system. Small-molecule inhibition of these pathways, e.g. JAK/STAT and COX-2 inhibitors, has been demonstrated in preclinical and clinical studies to provide better therapeutic results by targeting cancer progression due to inflammation. Regardless of these developments, there are still problems, such as resistance to medications, immunological tolerance, and the inability to monitor the inflammatory signaling in real-time. Pathway redundancies and pathway compensatory mechanisms present in the tumor microenvironment also limit the therapeutic efficacy of inflammation-targeted treatments. Further studies to prevent the mentioned obstacles are necessary in the creation of real-time monitoring devices, AI tools, and combination therapies, which would respond to several inflammatory pathways, at once. Introducing the specific predictive models and biomarker-controlled therapies to the personalized cancer treatment, one can refine the specific approach to the underlying inflammatory process and enhance the effectiveness of the treatment and the outcomes of the patients. To continue, more powerful research and clinical trials can be conducted to examine these methods and prove their efficiency in the struggle against the intricacies of the cancers induced by inflammation.

## REFERENCES


[1] Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646–674. https://doi.org/10.1016/j.cell.2011.02.013

[2] Greten FR, Grivennikov SI. Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity 2019; 51(1): 27–41. https://doi.org/10.1016/j.immuni.2019.06.025

[3] Karin M, Clevers H. Reparative inflammation takes charge of tissue regeneration. Nature 2016; 529(7586): 307–315. https://doi.org/10.1038/nature17039

[4] DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunological Reviews 2012; 246(1): 379–400. https://doi.org/10.1111/j.1600-065X.2012.01099.x

[5] Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews Cancer 2009; 9(11): 798–809. https://doi.org/10.1038/nrc2734

[6] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454(7203): 436–444. https://doi.org/10.1038/nature07205

[7] Zhang Z, Liu M, An Y, Gao C, Wang T, Zhang Z, Wang G. Targeting immune microenvironment in cervical cancer: Current research and advances. Journal of Translational Medicine 2025; 23(1): 888. https://doi.org/10.1186/s12967-025-06896-3

[8] Chaudhary T, Das S, Mazumder A, Aggarwal S. Integrative Insights into Cancer Progression: Molecular Mechanisms, Epigenetic Regulation, and Emerging Therapeutic Targets. Current Cancer Therapy Reviews 2026. https://doi.org/10.2174/0115733947391658251027060002

[9] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140(6): 883–899. https://doi.org/10.1016/j.cell.2010.01.025

[10] Desai SA, Patel VP, Bhosle KP, Nagare SD, Thombare KC. The tumor microenvironment: shaping cancer progression and treatment response. Journal of Chemotherapy 2025; 37(1): 15-44. https://doi.org/10.1080/1120009X.2023.2300224

[11] Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Molecular Cancer 2013; 12: 86. https://doi.org/10.1186/1476-4598-12-86

[12] Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews Cancer 2001; 1(1): 11–21. https://doi.org/10.1038/35094017

[13] Mansouri S. Machine Learning Models for Early Breast Cancer Detection: Computational Approaches and Innovations. Journal of Wireless Mobile Networks, Ubiquitous Computing, and Dependable Applications 2025; 16(1): 331-343. https://doi.org/10.58346/JOWUA.2025.I1.020

[14] Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454(7203): 428–435. https://doi.org/10.1038/nature07201

[15] Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. MedComm 2021; 2(4): 618–653. https://doi.org/10.1002/mco2.104

[16] Sajna V, Dharmaraj A. Awareness of Central Sector Scheme among the Entrepreneurs in the MSME Sector: An Investigative Study. Indian Journal of Information Sources and Services 2024; 14(3): 115–122. https://doi.org/10.51983/ijiss-2024.14.3.16

[17] Taniguchi K, Karin M. NF-κB, inflammation, immunity, and cancer: coming of age. Nature Reviews Immunology 2018; 18(5): 309–324. https://doi.org/10.1038/nri.2017.142

[18] Turanli B. Decoding Systems Biology of Inflammation Signatures in Cancer Pathogenesis: Pan-Cancer Insights from 12 Common Cancers. Omics: A Journal of Integrative Biology 2023; 27(10): 483-93. https://doi.org/10.1089/omi.2023.0127

[19] Karin M, Greten FR. NF-κB: Linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology 2005; 5(10): 749–759. https://doi.org/10.1038/nri1703

[20] Hayden MS, Ghosh S. NF-κB in immunobiology. Cell Research 2012; 21(2): 223–244. https://doi.org/10.1038/cr.2011.13

[21] Baud V, Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nature Reviews Drug Discovery 2009; 8(1): 33–40. https://doi.org/10.1038/nrd2781

[22] Nandhinieswari S, Indumathi A. Bilevel optimized recursive feature eliminator for cervical cancer feature selection process. Archives for Technical Sciences 2024; 2(31): 311–328. https://doi.org/10.70102/afts.2024.1631.311

[23] Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation-have anti-inflammatory therapies come of age? Nature reviews Clinical Oncology 2021; 18(5): 261-79. https://doi.org/10.1038/s41571-020-00459-9

[24] Kaviya P, Pradeepa K, Preetha S, Rama Priya M. Influential Gene Identification for Cancer Classification by Machine Learning Algorithm. International Journal of Advances in Engineering and Emerging Technology 2020; 11(1): 43–48.

[25] Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology 2018; 15(4): 234–248. https://doi.org/10.1038/nrclinonc.2018.8

[26] Bromberg JF, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15(2): 79–80. https://doi.org/10.1016/j.ccr.2009.01.009

[27] Grivennikov S, Karin M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine & Growth Factor Reviews 2010; 21(1): 11–19. https://doi.org/10.1016/j.cytogfr.2009.11.005

[28] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2010; 454(7203): 436–444. https://doi.org/10.1038/nature07205

[29] Assegid W, Ketema G. Harnessing AI for Early Cancer Detection through Imaging and Genetics. Clinical Journal for Medicine, Health and Pharmacy 2023; 1(1): 1-15.

[30] Asiya, Sugitha N. Ensuring Data Integrity and Security in AI-Based Lung Cancer Nodule Classification and Detection in CT Imaging Systems. Journal of Internet Services and Information Security 2025; 15(1): 361-370. https://doi.org/10.58346/JISIS.2025.I1.023

[31] Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010; 363(8): 711-723. https://doi.org/10.1056/NEJMoa1003466

[32] Bonato V, Tang SY, Hsieh M, Zhang Y, Deng S. Experimental design considerations and statistical analyses in preclinical tumor growth inhibition studies. Pharmaceutical Statistics 2025; 24(1): e2399. https://doi.org/10.1002/pst.2399

[33] Guner A, Kim HI. Biomarkers for evaluating the inflammation status in patients with cancer. Journal of gastric cancer 2019; 19(3): 254-277. https://doi.org/10.5230/jgc.2019.19.e29

[34] Chaudhary PK, Kim S. An insight into GPCR and G-proteins as cancer drivers. Cells 2021; 10(12): 3288. https://doi.org/10.3390/cells10123288

Received on 10-01-2026 Accepted on 08-02-2026 Published on 06-03-2026

https://doi.org/10.30683/1929-2279.2026.15.07